
-
Paratek Pharmaceuticals NASDAQ:PRTK Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use.
Location: 75 Park Plz Ste 4, Massachusetts, 02116-3934, US | Website: https://paratekpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
126.6M
Avg Qtr Burn
N/A
Short % of Float
5.26%
Insider Ownership
11.70%
Institutional Own.
55.08%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Seysara (Sarecycline) Details Inflammatory Acne (Acne Vulgaris) | Approved Quarterly sales | |
Nuzyra (Omadacycline) Details Bacterial infection | Approved Quarterly sales | |
Nuzyra (Omadacycline) Details Pneumonia, Community acquired bacterial pneumonia | Approved Quarterly sales | |
Omadacycline (Nuzyra) Details Intestinal infection, Stomach, Digestive tract, Nontuberculous mycobacteria infections | Phase 2b Update |